Table 3.
Association between gout or hyperuricemia and dementia, different treatment/diagnosis groups
| Diagnosis (hyperuricemia or gout), Treatment regimen (antihyperuricemic drug use)a | Controls (n=110,112) (% from 137,640) |
Cases (n=27,528) (% from 137,640) |
OR (95% CI), adjusted | p-value, adjusted for covariates |
|---|---|---|---|---|
| D:0, T:0 | 81,091 (58.9) | 20,204 (14.7) | Ref | |
| D:0, T:1 < =qu < 4 | 2445 (1.8) | 629 (0.5) | 0.93 (0.85,1.02) | 0.11 |
| D:0, T:qu > =4 | 2084 (1.5) | 558 (0.4) | 0.95 (0.86,1.04) | 0.26 |
| D:1, T:0 | 10,385 (7.6) | 2590 (1.9) | 0.94 (0.89,0.98) | 0.0065 |
| D:1, T:1 < =qu < 4 | 4718 (3.4) | 1168 (0.9) | 0.89 (0.83,0.95) | < 0.001 |
| D:1, T:qu > =4 | 9389 (6.8) | 2379 (1.7) | 0.89 (0.85,0.94) | < 0.001 |
Global test: Wald Χ2 = 2403.13, DF = 14, p < 0.001
aTreatment: T:0 means no anti-hyperuricemic treatment, qu > =x: means x or more quarters with treatment in the observation period, D:0 means no hyperuricamia diagnosis